1. Integrating plasma proteomics with genome-wide association data to identify novel drug targets for inflammatory bowel disease
- Author
-
Zhongyuan Bai, Jiawei Hao, Miaoran Chen, Kaixin Yao, Leilei Zheng, Liu Liu, Jingxi Hu, Kaiqing Guo, Yongqiang Lv, and Feng Li
- Subjects
Crohn’s disease ,Inflammatory bowel disease ,Mendelian randomisation ,Proteome-wide association study ,Ulcerative colitis ,Medicine ,Science - Abstract
Abstract Inflammatory bowel disease (IBD) is a chronic disease that includes Crohn’s disease (CD) and ulcerative colitis (UC). Although genome-wide association studies (GWASs) have identified many relevant genetic risk loci, the impact of these loci on protein abundance and their potential utility as clinical therapeutic targets remain uncertain. Therefore, this study aimed to investigate the pathogenesis of IBD and identify effective therapeutic targets through a comprehensive and integrated analysis. We systematically integrated GWAS data related to IBD, UC and CD (N = 25,305) by the study of de Lange KM with the human blood proteome (N = 7213) by the Atherosclerosis Risk in Communities (ARIC) study. Proteome-wide association study (PWAS), mendelian randomisation (MR) and Bayesian colocalisation analysis were used to identify proteins contributing to the risk of IBD. Integrative analysis revealed that genetic variations in IBD, UC and CD affected the abundance of five (ERAP2, RIPK2, TALDO1, CADM2 and RHOC), three (VSIR, HGFAC and CADM2) and two (MST1 and FLRT3) cis-regulated plasma proteins, respectively (P
- Published
- 2024
- Full Text
- View/download PDF